Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Collegium Pharmaceutical (COLL) Accumulated Depreciation & Amortization (2016 - 2025)

Collegium Pharmaceutical has reported Accumulated Depreciation & Amortization over the past 11 years, most recently at $16.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 22.23% year-over-year to $16.5 million; the TTM value through Dec 2025 reached $16.5 million, up 22.23%, while the annual FY2025 figure was $16.5 million, 22.23% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $16.5 million at Collegium Pharmaceutical, up from $13.5 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $16.5 million in Q4 2025 and troughed at $4.7 million in Q4 2021.
  • A 5-year average of $10.2 million and a median of $9.7 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 53.66% in 2021 and later rose 22.23% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $4.7 million in 2021, then surged by 34.65% to $6.3 million in 2022, then surged by 53.06% to $9.7 million in 2023, then skyrocketed by 39.84% to $13.5 million in 2024, then rose by 22.23% to $16.5 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for COLL at $16.5 million in Q4 2025, $13.5 million in Q4 2024, and $9.7 million in Q4 2023.